Serum insulin‐like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma‐associated malnutrition and muscle wasting. Issue 3 (24th March 2021)

• Record Type: Journal Article
• Authors: Dong, Jie; Yu, Jie; Li, Zekun; Gao, Song; Wang, Hongwei; Yang, Shengyu; Wu, Liangliang; Lan, Chungen; Zhao, Tiansuo; Gao, Chuntao; Liu, Zhe; Wang, Xiuchao; Hao, Jihui
• Is Part Of: Journal of cachexia, sarcopenia and muscle. Volume 12:Issue 3(2021)
• Page Start: 704
• Page End: 716
• Publication Date: 2021-03-24
• Subjects: IGFBP2 -- PDAC -- Cachexia -- Malnutrition -- Muscle wasting -- Biomarker; Cachexia -- Periodicals; Muscles -- Aging -- Periodicals; Muscles -- Periodicals; Cachexia; Sarcopenia; Muscles; Cachexia; Muscles; Muscles -- Aging; Periodicals; Periodicals; 616
• DOI: 10.1002/jcsm.12692
• Languages: English
• ISSNs: 2190-5991

Abstract

Abstract: Background: Malnutrition and muscle wasting are common features frequently observed in pancreatic ductal adenocarcinoma (PDAC) patients with cancer cachexia. They are associated with reduced survival and quality of life. Nutrition therapy is an important part of multimodal cancer care in PDAC. However, due to the complexity of nutrition assessment, only 30–60% of patients with nutritional risks receive nutritional treatment at present. It is important to identify biomarkers that may be used to improve management of PDAC‐associated malnutrition. Serum insulin‐like growth factor binding protein 2 (IGFBP2) has emerged as a potential serum biomarker in a variety of tumours. However, its association with malnutrition and muscle wasting in PDAC is unclear. Methods: We evaluated the tumour IGFBP2 expression and serum IGFBP2 level in 98 PDAC patients using immunohistochemistry and enzyme‐linked immunosorbent assay and analysed the correlation between them. Furthermore, we explored the relationship between IGFBP2 of both tumour and serum and nutritional status (Patient‐Generated Subjective Global Assessment and skeletal muscle index). Pan02 IGFBP2 stable transfection cell lines, Pan02 PLV‐IGFBP2 cells, and PLKO‐IGFBP2 cells were injected subcutaneously into the flank of C57BL/6 mouse. Serum IGFBP2 levels, food intake, and body weight of these mice were measured. The degree of muscle atrophy is characterized by haematoxylin and eosin, Oil Red O, and Masson's trichrome staining. The mRNA and protein expression of several essential muscle‐related signal proteins such as atrogin‐1 and muscle RING finger 1 was measured. Results: Among 98 patients, we found that tumour IGFBP2 expression is related to plasma IGFBP2 levels ( r s = 0.562, P < 0.001), and they significantly increased among patients with Patient‐Generated Subjective Global Assessment ≥9 and correlated with overall survival. Moreover, serum IGFBP2 level is negatively correlated with skeletal muscle index ( r s = −0.600, P < 0.001) and Hounsfield units ( r s = −0.532, P < 0.001). In mice injected with Pan02 PLV‐IGFBP2 cell, circulating IGFBP2 was elevated while body weight and food intake were decreased when compared with Pan02 PLV‐Control group. These mice also exhibited significantly aggravated muscle fibre atrophy, lipid deposition, and increased collagen tissue, and the expression of mRNA and protein of atrogin‐1 and muscle RING finger 1 in the gastrocnemius muscle is increased. Conversely, these symptoms were alleviated in the PLKO‐IGFBP2 group. Conclusions: In the current study, there is a significant correlation between serum IGFBP2 levels, malnutrition, and muscle atrophy in PDAC. Our results suggested that serum IGFBP2 level might be a promising biomarker and intervention targets for PDAC‐associated severe malnutrition and muscle wasting.